AstraZeneca PLC (AZN)vsSS Innovations International Inc. Common Stock (SSII)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
SSII
SS Innovations International Inc. Common Stock
$3.78
-1.56%
HEALTHCARE · Cap: $788.52M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 124605% more annual revenue ($60.44B vs $48.47M). AZN leads profitability with a 17.2% profit margin vs -20.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SSII
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+87.1%
Fair Value
$25.71
Current Price
$3.78
$21.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 116.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 18.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -18.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SSII
The strongest argument for SSII centers on Revenue Growth, Debt/Equity. Revenue growth of 116.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SSII
The primary concerns for SSII are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while SSII is a hypergrowth play — different risk/reward profiles.
SSII carries more volatility with a beta of 0.68 — expect wider price swings.
SSII is growing revenue faster at 116.8% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 22/100), backed by strong 17.2% margins and 12.5% revenue growth. SSII offers better value entry with a 87.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
SS Innovations International Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
SS Innovations International, Inc., is a commercial-stage surgical robotics company in India and internationally. The company is headquartered in Gurugram, India.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?